|
|
Volumn 53, Issue 3, 2002, Pages 305-311
|
|
Early clinical experience with the novel NMDA receptor antagonist CNS 5161
|
|
Author keywords
Glutamate receptor; Neuroprotection; Stroke
|
|
Indexed keywords
CNS 5161;
N (2 CHLORO 5 (METHYLMERCAPTO)PHENYL) N' (3 (METHYLMERCAPTO)PHENYL) N' METHYLGUANIDINE;
N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;
PLACEBO;
UNCLASSIFIED DRUG;
ADULT;
ANTICONVULSANT ACTIVITY;
ARTICLE;
BODY WEIGHT;
BRAIN INJURY;
BRAIN ISCHEMIA;
CARDIOVASCULAR EFFECT;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIASTOLIC BLOOD PRESSURE;
DOSE RESPONSE;
DOUBLE BLIND PROCEDURE;
DROWSINESS;
DRUG CLEARANCE;
DRUG DISTRIBUTION;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
DYSESTHESIA;
FLUSHING;
HALF LIFE TIME;
HEADACHE;
HEMODYNAMICS;
HUMAN;
MALE;
MEAN ARTERIAL PRESSURE;
NEUROPROTECTION;
NORMAL HUMAN;
PARESTHESIA;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
SENSORY DYSFUNCTION;
SYSTOLIC BLOOD PRESSURE;
THROAT DISEASE;
VERTIGO;
ADOLESCENT;
ADULT;
AREA UNDER CURVE;
BLOOD PRESSURE;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DOUBLE-BLIND METHOD;
GUANIDINES;
HALF-LIFE;
HUMANS;
INJECTIONS, INTRAVENOUS;
MALE;
RECEPTORS, N-METHYL-D-ASPARTATE;
SULFHYDRYL COMPOUNDS;
|
|
EID: 0036119716
PISSN: 03065251
EISSN: None
Source Type: Journal
DOI: 10.1046/j.0306-5251.2001.01541.x Document Type: Article |
|
Times cited : (26)
|
|
References (7)
|
